NASA’s COVID-19 ventilator gains FDA approval for emergency use
The Food and Drug Administration yesterday approved for emergency use a ventilator specially developed by the National Aeronautics and Space Administration to treat COVID-19 patients.
NASA’s VITAL (Ventilator Intervention Technology Accessible Locally) system is designed to last three to four months and is specifically tailored for patients with COVID-19 by providing respiratory support for patients experiencing respiratory failure or insufficiency.
Additionally, the device is designed to be built with components outside the current medical device supply chain and thereby will not impact existing ventilator supply chains.
Related News Articles
Headline
Flu cases are growing or likely growing in 39 states, according to the latest Centers for Disease Control and Prevention data from Nov. 11. COVID-19…
Headline
The Food and Drug Administration yesterday published an announcement from Otsuka ICU Medical saying that the company issued a voluntary recall for a mislabeled…
Headline
A study published Oct. 30 by the American Heart Association found that people have an elevated risk of heart attack and stroke following flu and COVID-19…
Headline
The Centers for Disease Control and Prevention will update its immunization schedules for the COVID-19 and chickenpox vaccines to adopt recent recommendations…
Headline
The Food and Drug Administration today issued a request for public comment on a series of questions regarding current approaches to evaluating artificial…
Headline
The Food and Drug Administration yesterday announced that Olympus issued a global recall of its ViziShot 2 FLEX needles manufactured prior to May 12 following…